Chipmaker Qualcomm is reportedly talking to GlaxoSmithKline about setting up a $1 billion joint venture. The deal, reports of which were posted by two financial publications, would mark a continuation of Qualcomm's drive to tighten its ties to biopharma, which was given impetus last year when it set up a VC fund with Novartis and inked a deal with Roche.
The joint venture set up by Novartis and Qualcomm has teamed up with Lux Capital to funnel $6.5 million into Science 37. Los Angeles, CA-based Science 37 will use the cash to step up the expansion of its virtual, tech-enabled model of clinical trial services. Read more >>
POPULAR COMMENT THREADS
Big Pharma consortium TransCelerate BioPharma has released a portal through which research sites can interact with multiple clinical trial sponsors. The portal is intended to free clinical trial sites from the duplicated workload and administrative burdens associated with using a different portal for each of the sponsors with which they work.
The team behind a planned 10,000-person, 265,000-square-meter cancer research and care hub in London is looking for software developers to occupy some of the site. By housing software companies, biotechs, med-tech developers and other companies in part of the U.K.'s cancer research and care network, the team is aiming to better connect the public and private sectors.
Roche is reportedly considering continuing its sequencing dealmaking activity with a bid for Pacific Biosciences.
Bavarian Nordic has signed up to work with Evaxion Biotech on the development of a vaccine against methicillin-resistant Staphylococcus aureus (MRSA). The project is underpinned by Eden Technology, an in silico vaccine discovery platform that combines data, algorithms and deep learning to unearth antigens.
Jonathan Rothberg, the Yale University entrepreneur who set up 454 Life Sciences and Ion Torrent, has raised $40 million to bankroll his next venture, a tech-enabled drug discovery shop. The startup, LAM Therapeutics, is aiming to leverage advances in genome editing, sequencing, computer science and artificial intelligence to make drug discovery cheaper and more precise.
Illumina has signed deals to genotype the sample collections at four biobanks. Each of the projects is aiming to build a repository of linked genotypic and phenotypic data, with the sequencing results generated by Illumina being paired to electronic medical records (EMRs) possessed by the owners of the biobanks.
From Our Sister Sites
Mary Szela, the new CEO at Cambridge, MA-based Aegerion, has reached for the budget ax to help compensate for the rising tide of competition that has challenged its cholesterol drug Juxtapid. The company announced today that it is chopping about 25% of its staff--roughly 80 workers--as it whittles its roster of employees down to 230.
Contract drugmaker Recipharm is promising to spend $45 million (€40 million) over the next three years to improve drug traceability in an effort to comply with new regulations and combat the rise of fake medicines.